MDK and benign neoplasm: In distinguishing benign tumors from ovarian cancer, a marker panel that included MDK was found to have a significantly higher area under the curve (AUC) than either cancer antigen 125 (CA125) or human epididymis protein 4 (HE4), which are the standard biomarkers for ovarian cancer [146].